Global Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.

Published Oct 20, 2025

Length 199 Pages

SKU # APRC20556222

Description

Summary

According to APO Research, the global Primary Biliary Cirrhosis Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Primary Biliary Cirrhosis Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Primary Biliary Cirrhosis Drug market include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Primary Biliary Cirrhosis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Primary Biliary Cirrhosis Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Primary Biliary Cirrhosis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Primary Biliary Cirrhosis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Primary Biliary Cirrhosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Primary Biliary Cirrhosis Drug sales, projected growth trends, production technology, application and end-user industry.

Primary Biliary Cirrhosis Drug Segment by Company

AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Primary Biliary Cirrhosis Drug Segment by Type

Budesonide
NGM-282
MBX-8025
GSK-2330672
FFP-104
Others
Primary Biliary Cirrhosis Drug Segment by Application

Clinic
Hospital
Others
Primary Biliary Cirrhosis Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Primary Biliary Cirrhosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Primary Biliary Cirrhosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Primary Biliary Cirrhosis Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Primary Biliary Cirrhosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Primary Biliary Cirrhosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Primary Biliary Cirrhosis Drug industry.
Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Primary Biliary Cirrhosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Primary Biliary Cirrhosis Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

1 Market Overview: 1.1 Product Definition; 1.2 Global Market Growth Prospects; 1.2.1 Global Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 1.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume (2020-2031); 1.2.3 Global Primary Biliary Cirrhosis Drug Sales Average Price (2020-2031); 1.3 Assumptions and Limitations; 1.4 Study Goals and Objectives
2 Primary Biliary Cirrhosis Drug Market Dynamics: 2.1 Primary Biliary Cirrhosis Drug Industry Trends; 2.2 Primary Biliary Cirrhosis Drug Industry Drivers; 2.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges; 2.4 Primary Biliary Cirrhosis Drug Industry Restraints
3 Primary Biliary Cirrhosis Drug Market by Company: 3.1 Global Primary Biliary Cirrhosis Drug Company Revenue Ranking in 2024; 3.2 Global Primary Biliary Cirrhosis Drug Revenue by Company (2020-2025); 3.3 Global Primary Biliary Cirrhosis Drug Sales Volume by Company (2020-2025); 3.4 Global Primary Biliary Cirrhosis Drug Average Price by Company (2020-2025); 3.5 Global Primary Biliary Cirrhosis Drug Company Ranking (2023-2025); 3.6 Global Primary Biliary Cirrhosis Drug Company Manufacturing Base and Headquarters; 3.7 Global Primary Biliary Cirrhosis Drug Company Product Type and Application; 3.8 Global Primary Biliary Cirrhosis Drug Company Establishment Date; 3.9 Market Competitive Analysis; 3.9.1 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI); 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024; 3.9.3 2024 Primary Biliary Cirrhosis Drug Tier 1, Tier 2, and Tier 3 Companies; 3.10 Mergers and Acquisitions Expansion
4 Primary Biliary Cirrhosis Drug Market by Type: 4.1 Primary Biliary Cirrhosis Drug Type Introduction; 4.1.1 Budesonide; 4.1.2 NGM-282; 4.1.3 MBX-8025; 4.1.4 GSK-2330672; 4.1.5 FFP-104; 4.1.6 Others; 4.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Type; 4.2.1 Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2020 VS 2024 VS 2031); 4.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Type (2020-2031); 4.2.3 Global Primary Biliary Cirrhosis Drug Sales Volume Share by Type (2020-2031); 4.3 Global Primary Biliary Cirrhosis Drug Sales Value by Type; 4.3.1 Global Primary Biliary Cirrhosis Drug Sales Value by Type (2020 VS 2024 VS 2031); 4.3.2 Global Primary Biliary Cirrhosis Drug Sales Value by Type (2020-2031); 4.3.3 Global Primary Biliary Cirrhosis Drug Sales Value Share by Type (2020-2031)
5 Primary Biliary Cirrhosis Drug Market by Application: 5.1 Primary Biliary Cirrhosis Drug Application Introduction; 5.1.1 Clinic; 5.1.2 Hospital; 5.1.3 Others; 5.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Application; 5.2.1 Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2020 VS 2024 VS 2031); 5.2.2 Global Primary Biliary Cirrhosis Drug Sales Volume by Application (2020-2031); 5.2.3 Global Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2020-2031); 5.3 Global Primary Biliary Cirrhosis Drug Sales Value by Application; 5.3.1 Global Primary Biliary Cirrhosis Drug Sales Value by Application (2020 VS 2024 VS 2031); 5.3.2 Global Primary Biliary Cirrhosis Drug Sales Value by Application (2020-2031); 5.3.3 Global Primary Biliary Cirrhosis Drug Sales Value Share by Application (2020-2031)
6 Primary Biliary Cirrhosis Drug Regional Sales and Value Analysis: 6.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2020 VS 2024 VS 2031; 6.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2020-2031); 6.2.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2020-2025; 6.2.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2026-2031); 6.3 Global Primary Biliary Cirrhosis Drug Sales Value by Region: 2020 VS 2024 VS 2031; 6.4 Global Primary Biliary Cirrhosis Drug Sales Value by Region (2020-2031); 6.4.1 Global Primary Biliary Cirrhosis Drug Sales Value by Region: 2020-2025; 6.4.2 Global Primary Biliary Cirrhosis Drug Sales Value by Region (2026-2031); 6.5 Global Primary Biliary Cirrhosis Drug Market Price Analysis by Region (2020-2025); 6.6 North America; 6.6.1 North America Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 6.6.2 North America Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2024 VS 2031; 6.7 Europe; 6.7.1 Europe Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 6.7.2 Europe Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2024 VS 2031; 6.8 Asia-Pacific; 6.8.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 6.8.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2024 VS 2031; 6.9 South America; 6.9.1 South America Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 6.9.2 South America Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2024 VS 2031; 6.10 Middle East & Africa; 6.10.1 Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value (2020-2031); 6.10.2 Middle East & Africa Primary Biliary Cirrhosis Drug Sales Value Share by Country, 2024 VS 2031
7 Primary Biliary Cirrhosis Drug Country-level Sales and Value Analysis: 7.1 Global Primary Biliary Cirrhosis Drug Sales by Country: 2020 VS 2024 VS 2031; 7.2 Global Primary Biliary Cirrhosis Drug Sales Value by Country: 2020 VS 2024 VS 2031; 7.3 Global Primary Biliary Cirrhosis Drug Sales by Country (2020-2031); 7.3.1 Global Primary Biliary Cirrhosis Drug Sales by Country (2020-2025); 7.3.2 Global Primary Biliary Cirrhosis Drug Sales by Country (2026-2031); 7.4 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2020-2031); 7.4.1 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2020-2025); 7.4.2 Global Primary Biliary Cirrhosis Drug Sales Value by Country (2026-2031); 7.5 USA; 7.5.1 USA Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.5.2 USA Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.5.3 USA Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.6 Canada; 7.6.1 Canada Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.6.2 Canada Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.6.3 Canada Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.7 Mexico; 7.6.1 Mexico Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.6.2 Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.6.3 Mexico Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.8 Germany; 7.8.1 Germany Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.8.2 Germany Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.8.3 Germany Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.9 France; 7.9.1 France Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.9.2 France Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.9.3 France Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.10 U.K.; 7.10.1 U.K. Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.10.2 U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.10.3 U.K. Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.11 Italy; 7.11.1 Italy Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.11.2 Italy Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.11.3 Italy Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.12 Spain; 7.12.1 Spain Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.12.2 Spain Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.12.3 Spain Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.13 Russia; 7.13.1 Russia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.13.2 Russia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.13.3 Russia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.14 Netherlands; 7.14.1 Netherlands Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.14.2 Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.14.3 Netherlands Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.15 Nordic Countries; 7.15.1 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.15.2 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.15.3 Nordic Countries Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.16 China; 7.16.1 China Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.16.2 China Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.16.3 China Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.17 Japan; 7.17.1 Japan Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.17.2 Japan Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.17.3 Japan Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.18 South Korea; 7.18.1 South Korea Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.18.2 South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.18.3 South Korea Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.19 India; 7.19.1 India Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.19.2 India Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.19.3 India Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.20 Australia; 7.20.1 Australia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.20.2 Australia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.20.3 Australia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.21 Southeast Asia; 7.21.1 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.21.2 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.21.3 Southeast Asia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.22 Brazil; 7.22.1 Brazil Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.22.2 Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.22.3 Brazil Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.23 Argentina; 7.23.1 Argentina Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.23.2 Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.23.3 Argentina Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.24 Chile; 7.24.1 Chile Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.24.2 Chile Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.24.3 Chile Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.25 Colombia; 7.25.1 Colombia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.25.2 Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.25.3 Colombia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.26 Peru; 7.26.1 Peru Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.26.2 Peru Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.26.3 Peru Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.27 Saudi Arabia; 7.27.1 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.27.2 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.27.3 Saudi Arabia Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.28 Israel; 7.28.1 Israel Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.28.2 Israel Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.28.3 Israel Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.29 UAE; 7.29.1 UAE Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.29.2 UAE Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.29.3 UAE Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.30 Turkey; 7.30.1 Turkey Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.30.2 Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.30.3 Turkey Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.31 Iran; 7.31.1 Iran Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.31.2 Iran Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.31.3 Iran Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031; 7.32 Egypt; 7.32.1 Egypt Primary Biliary Cirrhosis Drug Sales Value Growth Rate (2020-2031); 7.32.2 Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Type, 2024 VS 2031; 7.32.3 Egypt Primary Biliary Cirrhosis Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles: 8.1 AlbireoPharma; 8.1.1 AlbireoPharma Comapny Information; 8.1.2 AlbireoPharma Business Overview; 8.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio; 8.1.5 AlbireoPharma Recent Developments; 8.2 CymaBay Therapeutics, Inc.; 8.2.1 CymaBay Therapeutics, Inc. Comapny Information; 8.2.2 CymaBay Therapeutics, Inc. Business Overview; 8.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio; 8.2.5 CymaBay Therapeutics, Inc. Recent Developments; 8.3 Dr. Falk Pharma GmbH; 8.3.1 Dr. Falk Pharma GmbH Comapny Information; 8.3.2 Dr. Falk Pharma GmbH Business Overview; 8.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio; 8.3.5 Dr. Falk Pharma GmbH Recent Developments; 8.4 Enanta Pharmaceuticals, Inc.; 8.4.1 Enanta Pharmaceuticals, Inc. Comapny Information; 8.4.2 Enanta Pharmaceuticals, Inc. Business Overview; 8.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio; 8.4.5 Enanta Pharmaceuticals, Inc. Recent Developments; 8.5 Intercept Pharmaceuticals, Inc.; 8.5.1 Intercept Pharmaceuticals, Inc. Comapny Information; 8.5.2 Intercept Pharmaceuticals, Inc. Business Overview; 8.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio; 8.5.5 Intercept Pharmaceuticals, Inc. Recent Developments; 8.6 MediGene AG; 8.6.1 MediGene AG Comapny Information; 8.6.2 MediGene AG Business Overview; 8.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio; 8.6.5 MediGene AG Recent Developments; 8.7 NGM Biopharmaceuticals, Inc.; 8.7.1 NGM Biopharmaceuticals, Inc. Comapny Information; 8.7.2 NGM Biopharmaceuticals, Inc. Business Overview; 8.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio; 8.7.5 NGM Biopharmaceuticals, Inc. Recent Developments; 8.8 Virobay Inc.; 8.8.1 Virobay Inc. Comapny Information; 8.8.2 Virobay Inc. Business Overview; 8.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio; 8.8.5 Virobay Inc. Recent Developments; 8.9 GlaxoSmithKline Plc; 8.9.1 GlaxoSmithKline Plc Comapny Information; 8.9.2 GlaxoSmithKline Plc Business Overview; 8.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio; 8.9.5 GlaxoSmithKline Plc Recent Developments; 8.10 Johnson & Johnson; 8.10.1 Johnson & Johnson Comapny Information; 8.10.2 Johnson & Johnson Business Overview; 8.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Value and Gross Margin (2020-2025); 8.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio; 8.10.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis: 9.1 Primary Biliary Cirrhosis Drug Value Chain Analysis; 9.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials; 9.1.2 Raw Materials Key Suppliers; 9.1.3 Manufacturing Cost Structure; 9.1.4 Primary Biliary Cirrhosis Drug Sales Mode & Process; 9.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis; 9.2.1 Direct Comparison with Distribution Share; 9.2.2 Primary Biliary Cirrhosis Drug Distributors; 9.2.3 Primary Biliary Cirrhosis Drug Customers
10 Concluding Insights
11 Appendix: 11.1 Reasons for Doing This Study; 11.2 Research Methodology; 11.3 Research Process; 11.4 Authors List of This Report; 11.5 Data Source; 11.5.1 Secondary Sources; 11.5.2 Primary Sources

Pricing

Currency Rates

Single User Email from Publisher $4,250
Multi User License Fulfilled by Publisher $6,375
Global Site License Email from Publisher $8,500

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now